☆ 4.5 Article

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines

TRANSLATIONAL ONCOLOGY (2022)

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors

Sally C. M. Lau et al.

Summary: Mutation subtypes, such as EGFR exon 20 and HER2, are associated with better response and progression-free survival in non-small-cell lung cancer patients treated with immune checkpoint inhibitors (ICIs), making ICIs an important therapeutic option for these patients.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Article Oncology

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial

Caicun Zhou et al.

Summary: This study evaluated the treatment outcomes and safety of mobocertinib in patients with previously treated EGFRex2Oins-positive mNSCLC, showing clinically meaningful benefit and manageable safety profile in this patient population.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park et al.

Summary: Amivantamab demonstrates robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations, even after progression on platinum-based chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology